Dr. Rebekka Schneider-Kramann
We aim to dissect mechanisms in the regulation of the hematopoietic stem cell in myeloid malignancies. It is a major goal of our lab to identify novel therapeutic targets to specifically eliminate the disease initiating cells and their supporting environment
In vivo studies & translation
We are using various transgenic mouse models for disease modeling and genetic fate tracing and validate findings in human tissue and blood samples.
Genomics & proteomics
We are performing various single cell genomic technologies and proteomics to understand cell-fate in disease, heterogeneity and cross-talk with the ultimate goal to identify novel biomarkers and therapeutic targets.
CRISPR CAS9 Gene Editing
We use in vitro and in vivo CRISPR/Cas9 gene editing to validate pathways and therapeutic targets.
3D cell-culture modeling & stem cells
We are working with 3D cell culture models of human and mouse cells for disease modeling, target validation and compound screening.